Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Non Freeze-Dried Live Attenuated Influenza Vaccine in Healthy People
NCT05056519Phase 1Unknown
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of live attenuated influenza vaccine in influenza (2 arms), sponsored by Changchun BCHT Biotechnology Co. Primary endpoints: Number of participants with adverse events at 31 days, Number of participants with laboratory examination abnormity at 3 days and 1 more. Status: unknown.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05056519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05056519.